Literature DB >> 1565816

The role of computed tomography (CT) in the investigation of unexplained haemoptysis.

A B Millar1, A E Boothroyd, D Edwards, M R Hetzel.   

Abstract

Forty patients with a history of haemoptysis, normal chest radiographs apart from evidence of chronic airflow limitation, and normal fibreoptic bronchoscopy (or blood alone in the bronchial tree) were investigated by computed tomography (CT). Abnormalities were seen in 20 (50%) of the CT scans. Seven of the patients had evidence of bronchiectasis (18%), one of whom also had a mass. In four (10%) cases a mass alone was detected (two tuberculous, two malignant). In a further four (10%) scans alveolar consolidation was present and in three cases abnormal vessels were detected (7.5%). One patient had cystic changes shown in their scan and multiple nodules were shown in the final patient. The contralateral lungs of 93 patients undergoing CT for pre-operative assessment of bronchogenic carcinoma were used as controls. In six (6%) of these patients abnormalities were detected by CT. Pleural nodules were observed in two patients, fat in the transverse fissure in another, atelectasis in two patients and an apical bulla in the other abnormal scan. The relative risk for patients with unexplained haemoptysis having abnormal CT scans compared to the control group of patients was 7.75. We conclude that computed tomography is of value in the investigation of patients with unexplained haemoptysis.

Entities:  

Mesh:

Year:  1992        PMID: 1565816     DOI: 10.1016/s0954-6111(06)80146-0

Source DB:  PubMed          Journal:  Respir Med        ISSN: 0954-6111            Impact factor:   3.415


  15 in total

1.  BTS guidelines for the management of pleural infection.

Authors:  C W H Davies; F V Gleeson; R J O Davies
Journal:  Thorax       Date:  2003-05       Impact factor: 9.139

2.  Guidelines for radiologically guided lung biopsy.

Authors:  A Manhire; M Charig; C Clelland; F Gleeson; R Miller; H Moss; K Pointon; C Richardson; E Sawicka
Journal:  Thorax       Date:  2003-11       Impact factor: 9.139

Review 3.  The pulmonary physician in critical care * Illustrative case 7: Assessment and management of massive haemoptysis.

Authors:  J L Lordan; A Gascoigne; P A Corris
Journal:  Thorax       Date:  2003-09       Impact factor: 9.139

Review 4.  Computed tomography of the airways.

Authors:  S A Worthy; C D Flower
Journal:  Eur Radiol       Date:  1996       Impact factor: 5.315

Review 5.  The Diagnosis and Treatment of Hemoptysis.

Authors:  Harald Ittrich; Maximilian Bockhorn; Hans Klose; Marcel Simon
Journal:  Dtsch Arztebl Int       Date:  2017-06-05       Impact factor: 5.594

Review 6.  A systematic approach to the management of massive hemoptysis.

Authors:  Christopher Radchenko; Abdul Hamid Alraiyes; Samira Shojaee
Journal:  J Thorac Dis       Date:  2017-09       Impact factor: 2.895

7.  Tacrolimus as a reinforcement therapy for a patient with MPO-ANCA-associated diffuse alveolar hemorrhage.

Authors:  Satoko Kawasaki; Hideki Nakamura; Emi Honda; Nozomi Iwanaga; Atsushi Kawakami; Hiroaki Ida; Tomoki Origuchi; Shoko Honda; Yoshiko Tsuchihashi; Hiroyuki Yoshimine; Katsumi Eguchi
Journal:  Clin Rheumatol       Date:  2006-08-10       Impact factor: 3.650

8.  Hemoptysis: comparison of diagnostic accuracy of multi detector CT scan and bronchoscopy.

Authors:  Mohammad Davoodi; Mohsen Kordi; Mohammad Momen Gharibvand; Maryam Haddadzadeh Shoushtari; Hamid Borsi; Mohammad Bahadoram
Journal:  Glob J Health Sci       Date:  2015-04-28

9.  Localization of bleeding sites in patients with hemoptysis based on their chest computed tomography findings: a retrospective cohort study.

Authors:  Hyun Ju Seon; Yun-Hyeon Kim; Yong-Soo Kwon
Journal:  BMC Pulm Med       Date:  2016-11-25       Impact factor: 3.317

10.  Bronchial artery embolization in life-threatening massive hemoptysis.

Authors:  Hossein Ghanaati; Ali Shakouri Rad; Kavous Firouznia; Amir Hossein Jalali
Journal:  Iran Red Crescent Med J       Date:  2013-12-05       Impact factor: 0.611

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.